- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03630523
Response of Immune System to Flu Vaccination in PHTS (RIPS)
August 10, 2018 updated by: Radboud University Medical Center
Registering the Immune Response to a Flu Vaccination Challenge in PTEN Hamartoma Tumour Syndrome
this study evaluates the cellular and humoral immune response to seasonal influenze vaccination in PTEN Hamartoma Tumor Syndrome.
All subjects will be administered flu vaccination, half of the subjects will be control subjects.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be diagnosed with PHTS based on genetic testing
- Must be a Radboudumc patient
- Must be 18 years or older
- Must be mentally competent
- Must have provided written informed consent to participate in the study
- Must be able to adhere to visit schedule and available to complete the study
Exclusion Criteria:
• Known history of significant medical disorder, which in the investigator's judgment might confound the results of the study or pose additional risk to the subject by participation in the study
- Known hypersensitivity to previous influenza vaccinations (Anaphylaxis)
- Must not be allergic to chicken eggwhite
- Pregnancy at start of study
- Immunocompromised patients and those receiving concomitant immunosuppressive therapy or other immune modulating drugs including chronic steroid treatment.
- Bleeding disorders including haemophilia and thrombocytopenia or treatment with anticoagulants(Due to risk of intramuscular hematoma after injection)
- Must not have received vaccination with attenuated pathogens in the 4 weeks leading up to study. (Measles, mumps, rubella, yellow fever, rotavirus, BCG, typhoid)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Vaccination
Arm contains all subjects; vaccination with Influvac Tetra will be administered at start of study, response will be measured in 7 and 21 days.
|
Tetravalent seasonal flu vaccination 2018/2019
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hemagglutination inhibition assay titre
Time Frame: 7 days
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proliferation assay
Time Frame: 21 days
|
21 days
|
interleukin profile
Time Frame: 21 days, 7 days
|
21 days, 7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
October 1, 2018
Primary Completion (ANTICIPATED)
January 1, 2019
Study Completion (ANTICIPATED)
January 1, 2019
Study Registration Dates
First Submitted
August 10, 2018
First Submitted That Met QC Criteria
August 10, 2018
First Posted (ACTUAL)
August 15, 2018
Study Record Updates
Last Update Posted (ACTUAL)
August 15, 2018
Last Update Submitted That Met QC Criteria
August 10, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL66559.091.18
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTEN Hamartoma Tumor Syndrome
-
Stanford UniversityNot yet recruitingPTEN Gene Mutation | PTEN Hamartoma Tumor Syndrome | PTEN Hamartoma SyndromeUnited States
-
University of South FloridaBoston Children's HospitalCompletedPTEN Gene MutationUnited States
-
Boston Children's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedPTEN Gene Mutation | PTEN Hamartoma Tumor SyndromeUnited States
-
John Carroll UniversityUniversity Hospital Southampton NHS Foundation TrustActive, not recruitingPTEN Hamartoma Tumor SyndromeUnited States, United Kingdom
-
Ohio State UniversityPfizer; PTEN ResearchActive, not recruitingCowden Syndrome | Polyposis | PTEN Gene Mutation | PTEN Hamartoma Tumor Syndrome | PTEN Hamartoma Syndrome | Bannayan Syndrome | Bannayan Zonana SyndromeUnited States
-
Boston Children's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingAutism | ASD | Macrocephaly | PTEN | PTEN Hamartoma Tumor SyndromeUnited States
-
Faeth TherapeuticsActive, not recruitingAdvanced Solid Tumor | PIK3CA Mutation | PTEN Loss of Function MutationUnited States
-
National Cancer Institute (NCI)CompletedHamartoma Syndrome, Multiple | Cowden's DiseaseUnited States
-
Novartis PharmaceuticalsCompletedBreast Cancer | Solid Tumors | Cowden SyndromeUnited States, Spain, Canada
-
National Human Genome Research Institute (NHGRI)Recruiting
Clinical Trials on Influvac Tetra
-
Parc Taulí Hospital UniversitariRecruitingSARS CoV 2 Infection | Apnea, Obstructive SleepSpain
-
BayerCureVacWithdrawnCoronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
University of SurreyCompleted
-
Solvay BiologicalsCompleted
-
University of Texas Southwestern Medical CenterTerminatedNeonatal Brachial Plexus PalsyUnited States
-
Abbott BiologicalsCompletedProphylaxis of InfluenzaGermany
-
SeqirusCompletedInfluenza, HumanUnited States, Estonia, Germany
-
AbbottCompleted
-
Abbott BiologicalsQuintiles, Inc.Completed